Announcement on behalf of OBIGEN that the Company’s Board of Directors resolved to appoint Mr. Frank Chen as Chairperson
2024.Jun.19
Announcement on behalf of OBIGEN of resolution to lift the non-competition restrictions for new directors
2024.Jun.19
Announcement on behalf of OBIGEN of re-election of directors and supervisors at the 2024 Annual General Shareholders’ meeting
2024.Jun.19
Announcement on behalf of OBIGEN of important resolutions of 2024 Annual Shareholders’ meeting and accumulated losses amounting to 50% of paid-in capital
2024.Jun.17
Announcement of 2024 Annual General Shareholders' meeting’s resolution to lift the non-competition restrictions for directors
2024.Jun.17
Announcement of the Company’s important resolutions of the 2024 Annual General Shareholders’ meeting.
2024.Jun.17
OBI-992 TROP2 ADC has been granted by TFDA to proceed to Phase I/II human clinical trial
2024.May.30
OBI has filed the application of a Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA
2024.May.30
Announcement on behalf of Amaran that the Company’s Board of Directors resolved to appoint Ms. Tessie Che as Chairperson
2024.May.29
Announcement on behalf of Amaran of re-election of directors and supervisors at the 2024 Annual General Shareholders’ meeting
